NCT06416241

Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein Occlusion

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 51 (actual)
• Sponsor: University of Athens · Academic / Other
• Sex: All
• Age: 18 Years – 95 Years
• Healthy volunteers: Accepted

Summary

Central retinal vein occlusion (CRVO) is a common retinal vascular disorder, occurring when there is a blockage to the main blood vessel that transports blood away from the retina. CRVO may cause visual impairment, especially due to macular edema (swelling of the macula due to fluid accumulation) and macular non-perfusion. Aflibercept has been found to improve visual acuity and reduce macular thickness in pivotal trials. The purpose of this study was to evaluate the efficacy and safety of intravitreal aflibercept in real-world, using a patient-fitted treatment regimen. Additionally, imaging parameters have been assessed before and after treatment with intravitreal aflibercept.

Conditions

• Retinal Vein Occlusion
• Vascular Occlusive Disease

Interventions

Type	Name	Description
DRUG	EYLEA 2 MG in 0.05 ML Injection	Intravitreal injection

Timeline

• Start date: 2017-01-01
• Primary completion: 2020-12-31
• Completion: 2024-03-31
• First posted: 2024-05-16
• Last updated: 2024-05-16

Regulatory

• FDA-regulated drug study